PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-0.49%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
0.49%
Gross profit growth below 50% of CRVO's 100.00%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-36.64%
R&D reduction while CRVO shows 5.59% growth. Joel Greenblatt would examine competitive risk.
-70.64%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-54.90%
Operating expenses reduction while CRVO shows 251.41% growth. Joel Greenblatt would examine advantage.
-54.90%
Total costs reduction while CRVO shows 15.98% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing D&A. Martin Whitman would check industry patterns.
54.90%
EBITDA growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
54.90%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-10.71%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
56.85%
Pre-tax income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
56.85%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
56.86%
EPS growth while CRVO declines. John Neff would investigate advantages.
56.86%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
-0.00%
Share count reduction while CRVO shows 2.84% change. Joel Greenblatt would examine strategy.
-0.00%
Diluted share reduction while CRVO shows 2.84% change. Joel Greenblatt would examine strategy.